# Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis

> **NCT07000630** · NA · TERMINATED · sponsor: **Peking University First Hospital** · enrollment: 3 (actual)

## Conditions studied

- Palmoplantar Pustulosis

## Interventions

- **DRUG:** Deucravacitinib

## Key facts

- **NCT ID:** NCT07000630
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-06-20
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-12-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Terminated early due to lack of expected efficacy. Three participants were enrolled but none completed the study.
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07000630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07000630, "Efficacy and Tolerability of Deucravacitinib in the Management of Palmoplantar Pustulosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07000630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*